LITERATURE REVIEW

Column Editor: David B. Cockram, MS, RD

Acute Renal Failure

Bock HA: Pathogenesls of acute renal failure: New aspects. Nephron 76:130-142, 1997

Su~mura K, Goto T, Kasai S" The activatmn of serum hepatocyte growth factor m acute renal failure. Nephron 76'364-365, 1997

Anemia and Erythropoietin

DeMarchi S, Cecchm E, Fallen E: Long-term effects of erythropoIetm therapy on fistula stenosis and plasma concen- trations of PDGF and MCP-I in hemodlalysls patients. JASN 8"1147 1156, 1997

Drueke TB, Barany P, Cazzola M: Management of iron deficiency m renal anemia: Guidehnes for the optimal therapeutic approach m erythropoletm-treated patients. Chn Nephrol 48:1-8, 1997

Ismafl N: Use of ewthropomtm, active vitamin D-3 metabohtes, and alkah agents in pre&aIysas patients Sere Nephrol 17:270-284, 1997

Jelkmann W, FandreyJ, Pagel H: Inhlbmon oferythropm- elm production by promflammatory cytoklnes. Gema- tologlya I Transfuzlologlya 42:16-19, 1997

Markowltz GS, Kahn GA, Femgold RE: An evaluation of the effectiveness of oral iron therapy in hemo&alysis patients receiwng recombinant human erythropoxetm. Chn Nephrol 48:34-40. 1997

Mmetn L: Erythropoletin treatment m renal anemia. How high should the target hematocnt be?J Nephrol 10:117-119. ~997

Venkatesan J, Hennch WE: Anemia, hypertension, and myocardial dysfimcnon in end-stage renal disease. Sem Nephrol 17:257-269, 1997

Chronic Renal Failure

DeSanto NG, Capasso G, Malnic G: Effect of an acute oral protein load on renal acidificatlo~ in healthy humans and m patients with chronic renal failure. JASN 8:784-792, 1997

Franz M, Horl WH: Proteinuna and the progression of chromc renal failure Nleren urid Hochdruckkrankheiten 26"257-259, 1997

�9 1998 b 7 the National Ktdney Fouudatlon, Inc, 1051-2276/98/0801-0008503 00/0

Ledermann S, Shaw V, Trompeter P,.: Low-protein &et and progression of chronic renal failure. Lancet 350:146-146, 1997

Locatelh F. Low-protein dmt and progression of chromc renal failure. Lancet 350:145-146, t 997

London GM, Drueke TB: Atherosclerosls and artel~oscle- rosls in chronic renal failure. Kidney Int 51:1678-1695. 1997

Miller SB, Rabkm R: The use of growth factors to increase glomerular filtration rate m chronic renal failure patients. Cur Oplmon Nephrol Hyperten 6.401-404, 1997

Nonoguchl H, Kiyama S, Naruse M: Low-protein diet and progression of chronic renal failure. Lancet 350:146-146. 1997

Parfitt AM: The hyperparathyroldlsm of chronic renal failure: A chsorder of growth Kidney Int 52:3-9, 1997

Pastons O, Aqmlani R, Foppa P: Altered muscle energ T metabohsm in post-absorptive patients with chronic renal failure. ScanJ Uroi Nephro131:281-287, 1997

Striker GE, Klahr S: Clinical trials in progression ofchromc renal failure. Adv Intern Med 42:555-595, 1997

Sukl WN: Use ofchuretlcs in chronic renal failure. Kidney Int $33-$35, 1997

Dialysis

Baltzan MA, Ahmed S, Baltzan R_B: Vanatlons in living donor graft rates by &alysls clinic: Effect on outcome and cost of chronic renal failure therapy. CIin Nephrol 47:351-355, 1997

BonnefontRousselot D, Jaudon MC, Issad B: Annoxldant status of elderly chronic renal patients treated by continuous ambulatory peritoneal &alys~s. Nephrol Dialysis Transplant 12"1399-1405, 1997

Lombardi M, Sisca S: Is HCV-mfectlon another reason to opt for peritoneal dlalysu m end-stage renal failure? Nephron 76:357-357, 1997

Nolph KD. Is total creatlnme clearance a poor index of adequacy m CAPD patients with residual renal function? Peritoneal Dial Int 17"232-233, 1997

Osterby P-.. P..enai changes m the diabetic kadney. Nephrol Dialysis Transplant 12.1282-1283, 1997

Pommer W, Bressel F. Chen F: There as room tBr improvement of preterrmnal care in diabetic panents with

Journal ofRe~al NutdUor~, Vol 8, No 1 (January), 1998 pp 43-45 4 5

44 LITERATURE R E V I E W

end-stage renal failure--The epldemlologacal evidence in Germany. Nephrol Dialysis Transplant 12:1318-1320, 1997

1Lutkowskl B, Puka J, Lao M: Renal replacement therapy m an era of socioeconomic changes--P,,eport from the Polish registry. Nephrol Dialysis Transplant 12:1105-1108. 1997

Vmga J, Goncalves N, Gomes In: Sleep disturbances in end-stage renal disease panents on hemodialysls. Dialysis Transplant 26:380, 1997

Yagi N, Paganini EP: Acute dialysis and conunuous renal replacement: The emergence of new technology involving the nephrologlst m the intensive care setting. Sere Nephrol 17:306-320, 1997

Lipids

Balaskas EV, Barmhas GI, Tourkantoms A: Management of lipid abnormalities in patients on CAPD. Peritoneal Dial Int 17:308-309, 1997

Hohage H, Ark M, Bruckner D. Effects of cyctosporin A and FK 506 on lipid metabolism and fibrmogen in kidney transplant recipients. Clin Transplant 11:225-230, 1997

Irish AB, Sxmons LA: Chronic renal disease and cardiovas- cular complications: Inewtable or preventable? Now is the time for some intervention studies. Aus NZ J Med 27:273- 274, 1997

Kagan A, Ehmalech E, Lerner Z: Residual renal function affects lipid profile in patients undergoing continuous ambu- latory peritoneal dialysis. Peritoneal Dial Int 17:243-249, 1997

Koch M, Gradaus F, Schoebel FC: Relevance of conven- tional cardiovascular risk factors for the prediction of coro- nary artery disease in diabetic patients on renal replacement therapy. Nephrol Dialysis Transplant 12:1187-1191, 1997

Nutrition: Clinical

Brocco E, Maloh M, Thomaseth K: Evaluation ofglomem- Jar filtration rate in non-insulin dependent diabetes-- lmplicanons for a study design in patients with rmcroalbumin- ana and hypertension during intervention trials. Dlab Nutr Metabol 10:65-77, 1997

Cano N, Leverve XM: Influence of chronic liver disease and chronic renal failure on nutrient metabolism and under- nutrition. Nutrition 13:381-383, 1997

Nutrition: Metabolism and Basic Science

Guerm M, Dachet C, Goulinet S: Famlhal lecithin: Cholesterol acyltransferase deficiency: Molecular analysis of a compound heterozygote: LCAT (Arg(147) ~ Trp) and LCAT (Tyr(171) "-'+ Stop). Atherosclerosls 131:85-95, 1997

Llang K, Vazlri ND: Gene expression of LDL, receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase m chronic renal failure. Nephrol Dialysis Transplant 12:1381- 1386, 1997

Nelson BC, Uden PC, Rockwell GF: Determination of oxalate in parenteral nutrition solutions by capillary electro- phoresls. J Chromatog A 771.285-299, 1997

Stenvmkel P. Helmburger O, Lonnqvlst F: Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure Nephrol Dialysis Transplant 12:1321-1325, 1997

WltkoSarsat V, DescampsLatscha B: Advanced oxldauon protein products: Novel uraermc toxins and pro-inflamma- tory mediators in chronic renal failure? Nephrol Dialysis Transplant 12:1310-1312, 1997

Pediatrics

Bald M, Gerigk M, Rascher ~,V: Elevated plasma concentra- nons ofneuropeptide Y m chll&en and adults with chronic and terminal renal failure. AmJ Kidney Dis 30:23-27, 1997

Englund MS, Berg UB, Arfwldson K: Renal functional reserve in transplanted and native single kidneys of children and adults. Ped Nephrol 11:312-317, 1997

Esen T, Krautschlck A, Alken P: Treatment update on pediatric urolithlasis. World J Uro115:195-202, 1997

Fine RN: Growth retardauon in children with chronic renal insufl~cmncy. Nephron 76:125-129, 1997

Furth SL, Powe NR, Hwang W: Does greater pe&atric experience influence treatment chmces in chronic disease management? Dialysis modahty choice for children with end-stage renal disease. Archlv Ped Adol Med 151.545-550, 1997

Laron Z, Khnger B, Silbergeld A: Opposing effects of growth hormone and insuhn-hke growth factor I on serum ]ipoprotein(A). J Ped Endocrm Metab 10:143-149, 1997

Powell DR, Lm F, Baker BK: Modulation of g-rowth factors by growth hormone in children with chromc renal failure. Kidney Int 51:1970-1979, 1997

\goolf AS: Molecular bases of human kidney malforma- tions. Ped Nephrol 11:373-376, 1997

Renal Bone Disease

Fourmer A, Opnsm R, Said S: Invasive versus non- lnvaslve diagnosis of renal bone disease Cur Opinion Nephrol Hyperten 6:333-348, 1997

Ittel TH, Wirtz DC, Schmitt H: Post-transplantation metabolic bone disease. Nleren und Hochdruckkrankheiten 26 192-200. 1997

LITERATURE REVI EW 45

Lewis SL, Kutvlrt SG, Seamer LC: Calcium metabohsm an blood and peritoneal lymphocytes from continuous ambula- tory peritoneal &alysis patients. Peratoneal Dial [nt 17:287- 294, 1997

gneserma a risk factor for adynamic bone &sease? ScanJ Urol Nephrol 31 275-280, 1997

Vitamins and Minerals

Macher MA, Baudoum V, Akll R: Current treatment of ren,d osteodystrophy m children. Archives de Pe&ame 4:$91-$94, 1997

Free LG: Gene therapy for human renal &sease? Don't catch your zinc finger m your leucine zapper. Am J Kadney Das 30"R44-R48, 1997

Morn H, Ishamura E, Inoue T: History of vitamin D treatment of renal osteodystrophy. Am J Nephrol 17:382- 386, 1997

Mucsl [, Hercz G: Adynamxc bone &sease: Pathogenesls, &agnosis and clinical relevance. Cur Opmlon Nephrol Hyperten 6:356-361, 1997

Navarro JF, Macla ML, Gallego E: Serum magnesmm concentration and PTH levels. Is long-term chromc hyperma-

Miller JA. Renal responses to sodmm restncuon m panents with early diabetes melhtus. JASN 8 749 755, 1997

Patel SR, Xu Y, Koemg iLJ: Effect of glucose on the function of the calclmol receptor and vlramm D metabolism. Kidney Int 52:79-86, 1997

Zhang DX, Okada S, Yu YY: Vitamin E inhibits apoptosis, DNA modification, and cancer incidence reduced by iron- mediated peroxldanon m Wistar rat kidney. Cancer Res 57:2410-2414, 1997